Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher C Butler

Showing results (291-300 of 301) with videos related to

Pageof 31
Sort By:
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|October 24, 2025
12 month follow-up of a randomised open label trial of nasal sprays and a behavioural intervention for respiratory tract infections (RTIs) in primary carePaul Little, Jane Louise Vennik, Kate Rumsby, et al.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|January 6, 2022
Clinical presentation, microbiological aetiology and disease course in patients with flu-like illness: a post hoc analysis of randomised controlled trial dataTheo J Verheij, Daniela Cianci, Alike W van der Velden, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|September 21, 2022
Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC<sup>4</sup>E trial in 15 European countriesXiao Li, Joke Bilcke, Alike W van der Velden, et al.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|January 16, 2024
Cost-utility analysis of molnupiravir for high-risk, community-based adults with COVID-19: an economic evaluation of the PANORAMIC trialMay Ee Png, Victoria Harris, Jenna Grabey, et al.
BMJ Open|July 14, 2018
Antivirals for influenza-Like Illness? A randomised Controlled trial of Clinical and Cost effectiveness in primary CarE (ALIC<sup>4</sup> E): the ALIC<sup>4</sup> E protocolEmily Bongard, Alike W van der Velden, Johanna Cook, et al.
Lancet (London, England)|December 17, 2019
Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: an open-label, pragmatic, randomised controlled trialChristopher C Butler, Alike W van der Velden, Emily Bongard, et al.
The Lancet. Infectious Diseases|September 12, 2024
Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trialVictoria Harris, Jane Holmes, Oghenekome Gbinigie-Thompson, et al.
The New England Journal of Medicine|April 22, 2026
Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk OutpatientsChristopher C Butler, Andrew D Pinto, Victoria Harris, et al.
BMJ Open|August 7, 2023
Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe diseaseOghenekome Gbinigie, Emma Ogburn, Julie Allen, et al.
Lancet (London, England)|December 25, 2022
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trialChristopher C Butler, F D Richard Hobbs, Oghenekome A Gbinigie, et al.
Pageof 31

Showing results (291-300 of 301) with videos related to

Sort By:
Pageof 31
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|October 24, 2025
12 month follow-up of a randomised open label trial of nasal sprays and a behavioural intervention for respiratory tract infections (RTIs) in primary carePaul Little, Jane Louise Vennik, Kate Rumsby, et al.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|January 6, 2022
Clinical presentation, microbiological aetiology and disease course in patients with flu-like illness: a post hoc analysis of randomised controlled trial dataTheo J Verheij, Daniela Cianci, Alike W van der Velden, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|September 21, 2022
Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC<sup>4</sup>E trial in 15 European countriesXiao Li, Joke Bilcke, Alike W van der Velden, et al.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|January 16, 2024
Cost-utility analysis of molnupiravir for high-risk, community-based adults with COVID-19: an economic evaluation of the PANORAMIC trialMay Ee Png, Victoria Harris, Jenna Grabey, et al.
BMJ Open|July 14, 2018
Antivirals for influenza-Like Illness? A randomised Controlled trial of Clinical and Cost effectiveness in primary CarE (ALIC<sup>4</sup> E): the ALIC<sup>4</sup> E protocolEmily Bongard, Alike W van der Velden, Johanna Cook, et al.
Lancet (London, England)|December 17, 2019
Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: an open-label, pragmatic, randomised controlled trialChristopher C Butler, Alike W van der Velden, Emily Bongard, et al.
The Lancet. Infectious Diseases|September 12, 2024
Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trialVictoria Harris, Jane Holmes, Oghenekome Gbinigie-Thompson, et al.
The New England Journal of Medicine|April 22, 2026
Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk OutpatientsChristopher C Butler, Andrew D Pinto, Victoria Harris, et al.
BMJ Open|August 7, 2023
Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe diseaseOghenekome Gbinigie, Emma Ogburn, Julie Allen, et al.
Lancet (London, England)|December 25, 2022
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trialChristopher C Butler, F D Richard Hobbs, Oghenekome A Gbinigie, et al.
Pageof 31